A full global competition is underway to develop safe vaccines against coronaviruses. The stakes cannot be higher than this. An effective vaccine or treatment against the virus that causes COVID-19 is needed to fully reinstate the economy and reinstate citizenship.

As the pace accelerates, USA TODAY summarizes some of the week’s most notable vaccine developments. Here’s what we know about Oxford University’s most promising vaccine candidates. These are considered by many to be ahead of the race, and international funding for the Maryland vaccine’s potential, and how vaccine opponents can continue to distribute COVID-19. Is shown.

Oxford vaccine protects monkeys

A single dose of a vaccine developed by Oxford University in the United Kingdom caused rhesus monkeys to develop antibodies to coronavirus within 28 days.

A vaccine called ChAdOx1 Seems to have prevented pneumonia Pulmonary inflammatory disease when animals are exposed to SAV-CoV-2, the virus that causes COVID-19.

The Oxford vaccine is based on vaccine platform researchers at the University’s Jenner Institute adapted to SARS-CoV-2.

The monkeys were tested at the Rocky Mountain Institute at the National Institute of Allergy and Infectious Diseases in Hamilton, MT.

Infected monkeys were compared to 3 control monkeys that did not receive the vaccine. Two out of three control monkeys developed pneumonia after exposure to the virus.

The survey results are Preprinted paper posted on Thursday Preprint server bioRxiv. Preprints are studies that have not undergone the usual peer-review process required for publication in medical or scientific journals. However, in the event of a coronavirus emergency, many researchers will announce the results as they become available.

UK: Vaccine could never come

Despite Oxford news, British Prime Minister Boris Johnson has admitted that the COVID-19 vaccine may never appear.

This statement was issued by the British government Detailed 50-Page 3-Step COVID-19 Recovery Plan It was launched on Wednesday, partially relaxing the country’s blockade restrictions.

Johnson said the only viable long-term solution would be a vaccine or cure, but “hope is not a plan,” while the country hoped to break through.

“The bulk vaccine or treatment could be more than a year ahead. Certainly, in the worst case scenario, we can’t find a vaccine. So our plan is to avoid this outcome. We have to do everything we can to tolerate the situation in which we are in this situation for a long time, “he said.

International Group Funds Maryland Vaccine Initiative

Maryland-based vaccine company Novavax receives up to $ 388 million from the International Coalition for Epidemic Preparedness (CEPI) to continue developing and manufacturing NVX-CoV2373, Novovex’s COVID-19 vaccine candidate I will.

The company said the potential vaccine has been successful in animal models. Phase 1 clinical trials are scheduled to begin in Australia in May.

Based in Norway, CEPI is a partnership between public, private, charitable and civil society organizations. It was launched in 2017 to prevent future epidemics and develop vaccines that ensure access to vaccines in low and middle income countries. Nine partnerships have been started to develop a vaccine against SARS-CoV-2.

WHO Vaccine Candidate Tracker

World Health Organization List of vaccine candidates COVID-19 remained stable in eight potential products in early human trials. Includes 3 from China, 2 from the US, 1 from the UK and 1 from Europe.

The list also includes vaccines that may be in preclinical evaluation. That is, it is still being tested in cell culture or animal laboratories. This week the number has increased by 8, from 102 on May 11 to 110 on May 15.

April 20th, when the list was first published, included 5 candidates in an early human trial, with 71 still in the lab.

Anti-boxers can compromise herd immunity

Most Americans are keen on a vaccine against SARS-CoV-2, the virus that causes COVID-19.

However, many say that this is not the case in some minorities who distrust vaccine safety. Voted by Yahoo News / YouGov 19% of Americans said they would not be vaccinated against SARS-CoV-2. Another 26% said they were not confident.

Votes made by Morning consultation 64% of Americans said they would be vaccinated, but 14% would not. The rest is undecided.

This may impede efforts to reduce the spread of disease in the country. Experts believe that 70% of the population will need to be vaccinated or recover from cases to prevent the spread of the disease.

America is far from the so-called herd immunity, where enough people are so immune that the virus can no longer spread freely. According to researchers Johns Hopkins UniversityIn that case, we need to protect 200 million Americans.

Email Elizabeth Weise ([email protected]) to submit a weekly summary development version or share other vaccine news

Read or share this story: https://www.usatoday.com/story/money/2020/05/16/coronavirus-vaccine-updates-oxford-covid-19-vaccine-protects-monkeys/5202831002/